Clover Biopharmaceuticals Ltd

Clover Biopharmaceuticals, Ltd. is a biotechnology company that researches, develops, manufactures, and commercializes vaccines in Mainland China and internationally. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated influenza vaccine; and SCB-219M, a bispecific Fc-fusion protein thrombocytopenia receptor agonist mimetic for cancer patients with chemotherapy-induced thrombocytopenia. The company is also developing SCB-2023B for COVID-19, SCB-1019 as a protein-based vaccine platform based on naturally trimerization-dependent targets, and SCB-1001 for rabies. In addition, it sells biopharmaceutical drugs. Founded in 2007, it is headquartered in Shanghai, the People's Republic of China.